

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

☐ Form 3 Holdings Reported.

☒ Form 4 Transactions Reported.

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0362
Estimated average burden
hours per response: 1.0

1. Name and Address of Reporting Person* <u>Galante Joseph C</u> (Last) (First) (Middle) <u>2525 WEST END AVENUE</u> <u>SUITE 950</u> (Street) <u>NASHVILLE TN 37203</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CUMBERLAND PHARMACEUTICALS</u> <u>INC [CPIX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) <u>12/31/2020</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Amount	(A) or (D)	Price			
Common Stock	11/20/2021		P4	75 ⁽¹⁾⁽²⁾	A	\$3.02	29,467	D	
Common Stock	11/23/2020		P4	75 ⁽¹⁾	A	\$3.03	29,542	D	
Common Stock	11/24/2020		P4	75 ⁽¹⁾	A	\$3.03	29,617	D	
Common Stock	11/25/2020		P4	75 ⁽¹⁾	A	\$3.01	29,692	D	
Common Stock	11/27/2020		P4	75 ⁽¹⁾	A	\$3.01	29,767	D	
Common Stock	11/30/2020		P4	75 ⁽¹⁾	A	\$3.05	29,842	D	
Common Stock	12/01/2020		P4	75 ⁽¹⁾	A	\$3.01	29,917	D	
Common Stock	12/02/2020		P4	75 ⁽¹⁾	A	\$3.03	29,992	D	
Common Stock	12/03/2020		P4	75 ⁽¹⁾	A	\$3.02	30,067	D	
Common Stock	12/04/2020		P4	75 ⁽¹⁾	A	\$3.02	30,142	D	
Common Stock	12/07/2020		P4	75 ⁽¹⁾	A	\$3.01	30,217	D	
Common Stock	12/08/2020		P4	75 ⁽¹⁾	A	\$3.05	30,292	D	
Common Stock	12/09/2020		P4	75 ⁽¹⁾	A	\$3.03	30,367	D	
Common Stock	12/10/2020		P4	75 ⁽¹⁾	A	\$3.05	30,442	D	
Common Stock	12/11/2020		P4	75 ⁽¹⁾	A	\$3.04	30,517	D	
Common Stock	12/14/2020		P4	75 ⁽¹⁾	A	\$3.04	30,592	D	
Common Stock	12/15/2020		P4	75 ⁽¹⁾	A	\$3.03	30,667	D	
Common Stock	12/16/2020		P4	75 ⁽¹⁾	A	\$3.03	30,742	D	
Common Stock	12/17/2020		P4	75 ⁽¹⁾	A	\$3.13	30,817	D	
Common Stock	12/18/2020		P4	75 ⁽¹⁾	A	\$3.17	30,892	D	
Common Stock	12/21/2020		P4	75 ⁽¹⁾	A	\$3.15	30,967	D	
Common Stock	12/22/2020		P4	75 ⁽¹⁾	A	\$3.13	31,042	D	
Common Stock	12/23/2020		P4	75 ⁽¹⁾	A	\$3.13	31,117	D	
Common Stock	12/24/2020		P4	75 ⁽¹⁾	A	\$3.11	31,192	D	
Common Stock	12/28/2020		P4	75 ⁽¹⁾	A	\$3.11	31,267	D	
Common Stock	12/29/2020		P4	75 ⁽¹⁾	A	\$3.05	31,342	D	
Common Stock	12/30/2020		P4	75 ⁽¹⁾	A	\$3.08	31,417	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Deemed Execution Date, if any (Month/Day/Year)	5. Transaction Code (Instr. 8)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Underlying Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Underlying Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Explanation of Responses:										
1. The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020.										
2. Filing 3 of 3										
Remarks:										

[Joseph C. Galante by /s/](#)
[Michael Bonner as attorney-in-fact](#) [02/05/2021](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.